Downregulation of BLM RecQ helicase inhibits proliferation, promotes the apoptosis and enhances the sensitivity of bladder cancer cells to cisplatin

Feng,Sujuan; Qian,Xiaosong; Feng,Dalin; Zhang,Xiaodong

doi:10.3892/mmr.2022.12829

Downregulation of BLM RecQ helicase inhibits proliferation, promotes the apoptosis and enhances the sensitivity of bladder cancer cells to cisplatin

Authors:
- Sujuan Feng
- Xiaosong Qian
- Dalin Feng
- Xiaodong Zhang
View Affiliations

Affiliations: Department of Urology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China
Published online on: August 17, 2022 https://doi.org/10.3892/mmr.2022.12829
Article Number: 313
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bloom syndrome protein (BLM) is known to maintain genomic integrity including DNA repair, recombination, replication and transcription. Its dysregulation affects the genomic instability of cells, which results in a high risk of developing various types of cancer and even Bloom syndrome. However, to date, to the best of our knowledge, no association has been made between human BLM and bladder cancer. Thus, the aim of the present study was to investigate the role of BLM in human bladder cancer. The expression pattern of BLM in bladder cancer tissue was detected by immunohistochemistry. The viability, proliferation, cell cycle and apoptosis of bladder cancer cell lines were determined by Cell Counting Kit‑8, EdU and flow cytometry following transfection of BLM small interfering RNA. Finally, the effect of BLM on sensitivity of bladder cancer cell lines to cisplatin was investigated by reverse transcription‑quantitative PCR and western blot. It was demonstrated that the expression of BLM in human bladder cancer was increased compared with adjacent healthy bladder tissues. In addition, silencing of BLM inhibited the proliferation and promoted the apoptosis of bladder cancer cells and it also enhanced the sensitivity of bladder cancer cells to cisplatin. Together, the findings of the present study demonstrated that the regulation of BLM activity may have potential for use as a novel therapeutic target and a predictor for the prognosis of bladder cancer.

View Figures

View References

1	Leal J, Luengo-Fernandez R, Sullivan R and Witjes JA: Economic burden of bladder cancer across the European union. Eur Urol. 69:438–447. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Berdik C: Unlocking bladder cancer. Nature. 551:S34–S35. 2017. View Article : Google Scholar : PubMed/NCBI
4	Sameni S and Hande MP: Plumbagin triggers DNA damage response, telomere dysfunction and genome instability of human breast cancer cells. Biomed Pharmacother. 82:256–268. 2016. View Article : Google Scholar : PubMed/NCBI
5	Marzec P, Armenise C, Pérot G, Roumelioti FM, Basyuk E, Gagos S, Chibon F and Déjardin J: Nuclear-receptor-mediated telomere insertion leads to genome instability in ALT cancers. Cell. 160:913–927. 2015. View Article : Google Scholar : PubMed/NCBI
6	Fujii Y: Prediction models for progression of non-muscle-invasive bladder cancer: A review. Int J Urol. 25:212–218. 2018. View Article : Google Scholar : PubMed/NCBI
7	Knowles MA and Hurst CD: Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
8	Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, et al: Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci USA. 111:E672–E681. 2014. View Article : Google Scholar : PubMed/NCBI
9	Nagata M, Muto S and Horie S: Molecular biomarkers in bladder cancer: Novel potential indicators of prognosis and treatment outcomes. Dis Markers. 2016:82058362016. View Article : Google Scholar : PubMed/NCBI
10	Newman JA and Gileadi O: RecQ helicases in DNA repair and cancer targets. Essays Biochem. 64:819–830. 2020. View Article : Google Scholar : PubMed/NCBI
11	Larsen NB and Hickson ID: RecQ helicases: Conserved guardians of genomic integrity. In: DNA Helicases and DNA Motor Proteins. Advances in Experimental Medicine and Biology. Vol. 767. Spies M: Springer; New York, NY: pp. 161–184. 2013, View Article : Google Scholar : PubMed/NCBI
12	Croteau DL, Popuri V, Opresko PL and Bohr VA: Human RecQ helicases in DNA repair, recombination, and replication. Annu Rev Biochem. 83:519–552. 2014. View Article : Google Scholar : PubMed/NCBI
13	Krogh BO and Symington LS: Recombination proteins in yeast. Annu Rev Genet. 38:233–271. 2004. View Article : Google Scholar : PubMed/NCBI
14	Traverso G, Bettegowda C, Kraus J, Speicher MR, Kinzler KW, Vogelstein B and Lengauer C: Hyper-recombination and genetic instability in BLM-deficient epithelial cells. Cancer Res. 63:8578–8581. 2003.PubMed/NCBI
15	Hickson ID: RecQ helicases: Caretakers of the genome. Nat Rev Cancer. 3:169–178. 2003. View Article : Google Scholar : PubMed/NCBI
16	Chandra S, Priyadarshini R, Madhavan V, Tikoo S, Hussain M, Mudgal R, Modi P, Srivastava V and Sengupta S: Enhancement of c-Myc degradation by BLM helicase leads to delayed tumor initiation. J Cell Sci. 126:3782–3795. 2013.PubMed/NCBI
17	Turley H, Wu L, Canamero M, Gatter KC and Hickson ID: The distribution and expression of the Bloom's syndrome gene product in normal and neoplastic human cells. Br J Cancer. 85:261–265. 2001. View Article : Google Scholar : PubMed/NCBI
18	Anisimenko MS, Kozyakov AE, Paul GA and Kovalenko SP: The frequency of the BLM p.Q548X (c.1642C>T) mutation in breast cancer patients from Russia is no higher than in the general population. Breast Cancer Res Treat. 148:689–690. 2014. View Article : Google Scholar : PubMed/NCBI
19	Prokofyeva D, Bogdanova N, Dubrowinskaja N, Bermisheva M, Takhirova Z, Antonenkova N, Turmanov N, Datsyuk I, Gantsev S, Christiansen H, et al: Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom's syndrome, is associated with breast cancer in Slavic populations. Breast Cancer Res Treat. 137:533–539. 2013. View Article : Google Scholar : PubMed/NCBI
20	Mao FJ, Sidorova JM, Lauper JM, Emond MJ and Monnat RJ: The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage. Cancer Res. 70:6548–6555. 2010. View Article : Google Scholar : PubMed/NCBI
21	Wang X, Lu X, Zhou G, Lou H and Luo G: RECQL5 is an important determinant for camptothecin tolerance in human colorectal cancer cells. Biosci Rep. 31:363–369. 2011. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Kumari A, Owen N, Juarez E and McCullough AK: BLM protein mitigates formaldehyde-induced genomic instability. DNA Repair (Amst). 28:73–82. 2015. View Article : Google Scholar : PubMed/NCBI
24	Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Moseley PM, Aleskandarany MA, Green AR, Ball G, Alshareeda AT, Rakha EA, et al: Transcriptomic and protein expression analysis reveals clinicopathological significance of bloom syndrome helicase (BLM) in breast cancer. Mol Cancer Ther. 14:1057–1065. 2015. View Article : Google Scholar : PubMed/NCBI
25	Lao VV, Welcsh P, Luo Y, Carter KT, Dzieciatkowski S, Dintzis S, Meza J, Sarvetnick NE, Monnat RJ Jr, Loeb LA and Grady WM: Altered RECQ helicase expression in sporadic primary colorectal cancers. Transl Oncol. 6:458–469. 2013. View Article : Google Scholar : PubMed/NCBI
26	Singh DK, Popuri V, Kulikowicz T, Shevelev I, Ghosh AK, Ramamoorthy M, Rossi ML, Janscak P, Croteau DL and Bohr VA: The human RecQ helicases BLM and RECQL4 cooperate to preserve genome stability. Nucleic Acids Res. 40:6632–6648. 2012. View Article : Google Scholar : PubMed/NCBI
27	Saleh-Gohari N and Helleday T: Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res. 32:3683–3688. 2004. View Article : Google Scholar : PubMed/NCBI
28	Chen K, Xu H and Zhao J: Bloom syndrome protein activates AKT and PRAS40 in prostate cancer cells. Oxid Med Cell Longev. 2019.2019:3685817, 2019. View Article : Google Scholar
29	Roos WP and Kaina B: DNA damage-induced cell death by apoptosis. Trends Mol Med. 12:440–450. 2006. View Article : Google Scholar : PubMed/NCBI
30	Ma J, Setton J, Lee NY, Riaz N and Powell SN: The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun. 9:32922018. View Article : Google Scholar : PubMed/NCBI
31	Tikoo S and Sengupta S: Time to bloom. Genome Integr. 4:142010. View Article : Google Scholar : PubMed/NCBI
32	Böhm S and Bernstein KA: The role of post-translational modifications in fine-tuning BLM helicase function during DNA repair. DNA Repair (Amst). 22:123–132. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zhang W, Yang S and Liu J, Bao L, Lu H, Li H, Pan W, Jiao Y, He Z and Liu J: Screening antiproliferative drug for breast cancer from bisbenzylisoquinoline alkaloid tetrandrine and fangchinoline derivatives by targeting BLM helicase. BMC Cancer. 19:10092019. View Article : Google Scholar : PubMed/NCBI